Immunai

World Cancer Day is about progress. And progress starts with better insight. We’re proud to work with @bmsnews to apply AI-powered immune analysis that helps researchers better understand patient responses and support smarter therapy development. tinyurl.com/bde5uc8w

Understanding patient immune response is critical to clinical development (and difficult to do well). We’re collaborating with @BMSnews to support immune-driven clinical development, using AMICA-OS™, our immune system AI operating system. Read more: tinyurl.com/425vstak

@MountSinai , @WeillCornell Medicine, and Harvard’s @MassGeneral are the first academic partners in Immunai’s Grand Collaboration Initiative. We’re teaming up to apply single-cell immune insights at scale and accelerate discovery. The announcement: tinyurl.com/e5hmnh38

Big news: @Immunai has won the @FierceBiotech Life Sciences Award for AI Innovation. Fierce showcased our AMICA™ platform and its success in forecasting patient response - a major step toward more precise development. tinyurl.com/3z65bp5f

New in Blood Advances: our Immunai team, with Mount Sinai & Janssen R&D, identified immune features predicting long-term response to CAR T therapy in multiple myeloma. 🔗 ashpublications.org/bloodadvances/… #Immunai #CART #MultipleMyeloma #Immunotherapy #PrecisionMedicine

Immunai has been named a finalist in the @FierceHealth : Life Sciences Edition 2025 (AI Innovation category)! Our AMICA™, CT-OS™, and PE-OS™ platforms are driving a new wave of immune intelligence, where AI helps predict, not just treat, disease. bit.ly/3J1qPUc

Proud to expand our work with @AstraZeneca into inflammatory bowel disease. IBD affects 10M+ people worldwide, with many still cycling through treatments. With Immunai’s IDE™ and AMICA™, we’re uncovering and exploring new immune targets. @FierceBiotech: tinyurl.com/48htfzzy

Research in immunity can’t wait for funding. We launched the Grand Collaboration Initiative to give researchers free access to immune mapping tools: accelerating discoveries in cancer, autoimmunity, and beyond. More in @PharmaVoice tinyurl.com/mr455nr8

Research in immunity can’t wait for funding. Immunai’s Grand Collaboration Initiative is giving researchers free access to our immune mapping tools to speed discoveries in cancer, autoimmunity, and more. tinyurl.com/3k3mk5j8

Immunai’s Grand Collaboration is now open! Single-cell immune sequencing for academic researchers to advance immune system understanding. ✔️ High-resolution, multi-omic data 🧬 Enrichment of the AMICA atlas 🗓️ Applications due by Oct 1, 2025 #scRNAseq #Immunai #AcademicResearch

Excited to share our work at #BiomedIsrael! Elisha Nathan presents how Immunai de-risks immunotherapy development using AI + single-cell multi-omics. Powered by AMICA, the world’s largest clinical immune db. #Immunai #DrugDevelopment #Oncology #Autoimmune

Our CEO @NoamSolomon1 just joined a very impressive club: @INVIVOnow’s 2025 Rising Leaders💥 This list features 30 people shaking up biotech, medtech, and global health. Proud moment for the @Immunaitech team. bit.ly/4m2eNZm

At #DDW2025, Immunai & @AstraZeneca share new IBD research using single-cell data + functional genomics. Deleting one target reduced TNFα/IFNγ in macrophages - showing real therapeutic potential. 📷 Read more: eposters.ddw.org/ddw/2025/ddw-2…  #IBD #Immunology #DrugDiscovery #AIinBiotech

We’re teaming up with @parkerici to build one of the largest real-world single-cell datasets. Integrated into AMICA™, this will power immune insights across cancers, accelerating discovery + reducing trial risk genengnews.com/topics/cancer/…

🧬 Heading to #AACR25? Meet Immunai CEO Noam Solomon, CTO Adeeb Rahman, & VP BD Evan Zisholtz 📌 See our April 30 poster on predicting aPD1 response using a human ex vivo tumor model + multiomic data. #Immunotherapy #CancerResearch #Multiomics

After leading R&D at Pfizer, Dr. Mikael Dolsten is entering a new chapter. He’s joining Immunai’s board to help advance AI-powered drug development. Read about his move and outlook on the future of biopharma via @PharmaVoice: tinyurl.com/352t6hxc

Dr. Mikael Dolsten, a leader behind 35+ approved therapies, is bringing his expertise to Immunai’s Board. His experience in R&D and immunology will help us deepen AI’s role in drug discovery, bringing new treatments to patients faster. tinyurl.com/79c4sf4v

🧬 Inside Immunai kicks off 2025 with Eva Macuchova, our Scientific Team Lead! At Immunai, she’s helped standardize data & fuel AI-powered discoveries in cancer & inflammatory research. Crime novel lover, foodie, & data expert—join her team! tinyurl.com/yck83dwt

Immunai has been named Startup of the Week via @theinnovator⭐️ Read how Immunai is bridging the gap between computer science and life sciences to combat Eroom’s Law—the rising costs of drug development.bit.ly/4gbnwEm

Our CEO @NoamSolomon1 is headed to Davos to represent Immunai as part of the @WEF Unicorn Program with other high-growth companies shaping the future of their industries. Are you attending? tinyurl.com/2mmnvvc3